Global Cardiomyopathy Devices Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028

“Global Cardiomyopathy Devices Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028” is a recent report generated by MarketResearch.biz. The global cardiomyopathy devices market report has been segmented on the basis of type, diagnosis test, treatment, end user, and region

Request Covid - 19 Impact

Global Cardiomyopathy Devices Market: Overview

Incidences of cardiovascular diseases are increasing worldwide, according to the World Health Organization, 1every year 7.9 Mn die from CVDs, and 85% of all CVD deaths are caused due to heart attacks and strokes. Cardiomyopathy is a heart disease in which the heart muscle becomes hard and restricts the heart function which can later result in heart failure. There are various types of cardiomyopathy namely dilated, hypertrophic, restrictive cardiomyopathy, etc. Treatment for cardiomyopathy includes medication or surgical implants and in severe cases heart transplant.

Global Cardiomyopathy Devices Market: Dynamics

Major factor expected to drive growth of the global market is increasing incidences of cardiomyopathy cases and rising number of patients suffering from amyloidosis in developed countries. In addition, rising prevalence of various cardiovascular diseases such as coronary heart diseases, congestive heart failure, and heart failure and demand for minimally invasive surgical procedures are some other factors expected to further support growth of the target market.

Moreover, the availability of remote monitoring solutions is expected to further support growth of the global market to a certain extent.

However, high cost of devices and lack of awareness are major factors expected to hamper growth of the global market.

Technological advancements by major players and increasing R&D activities for advanced synthetic material are expected to create new opportunities in terms of revenue for players operating in the target market over the forecast period. In addition, rising expansion activities through strategic partnerships and agreements are expected to further support market growth to a certain extent.

Global Cardiomyopathy Devices Market: Segment

Among the type segments, the hypertrophic cardiomyopathy is expected to dominate in the target market over the forecast period.

Among the end user segments, the hospital segment is expected to dominate in the target market over the forecast period.

Global Cardiomyopathy Devices Market: Region

The market in North America is expected to dominate in the global market and is expected to continue its dominance over the forecast period. This can be attributed to the increasing number of patient suffering from amyloidosis. According to the American Medical Association, amyloidosis-related mortality reported from US death certificates significantly increased from 1.77 to 3.96%. In addition, well-developed healthcare infrastructure, favorable reimbursement policies, and the presence of major players operating in the countries in this region are some other factors.

The market in Asia Pacific is expected to witness faster growth, owing to low awareness related to cardiomyopathy devices and the presence of prominent players operating in emerging economies in this region. In addition, growing merger and acquisition activities between regional and international players in order to increase their customer base is expected to further support growth of the target market in this region to a certain extent.

Global Cardiomyopathy Devices Market Segmentation

Segmentation by type

• Dilated Cardiomyopathy
• Hypertrophic Cardiomyopathy
• Restrictive Cardiomyopathy
• Arrhythmogenic Right Ventricular Dysplasia
• Unclassified Cardiomyopathy

Segmentation by diagnosis test

• Chest X-Ray
• Echocardiogram
• Electrocardiogram (ECG)
• Treadmill Stress Test
• Cardiac Catheterization
• Cardiac MRI
• Cardiac Ct Scan
• Blood Tests
• Genetic Testing or Screening

Segmentation by treatment

• Medication
• Surgically Implanted Devices
  • Implantable Cardioverter-Defibrillator (ICD)
  • Ventricular Assist Device (VAD)
  • Pacemaker
• Nonsurgical Procedures
  • Septal Ablation
  • Radiofrequency Ablation
• Surgery
  • Septal Myectomy
  • Heart Transplant

Segmentation by end user

• Homecare
• Hospitals and Clinics
• Diagnostic Center

Segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Abbott Diagnostics Inc.
• Array Biopharma, Inc.
• Astrazeneca Plc
• Becton and Dickson & Co.
• Bg Medicine Inc.
• bioMérieux, Inc.
• Bio-Rad Laboratories, Inc.
• Boston Scientific Corporation
• Bristol-Myers Squibb Company
• Cisbio Bioassays SAS